DECADRON-LA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DECADRON-LA (DECADRON-LA).
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory and immunosuppressive effects; suppresses migration of polymorphonuclear leukocytes, reverses increased capillary permeability, and reduces cytokine production.
| Metabolism | Primarily hepatic, via CYP3A4. |
| Excretion | Renal (<5% unchanged), hepatic metabolism with inactive metabolites excreted renally and fecally; urine and bile are minor routes. Exact % not specified for Decadron-LA (dexamethasone acetate), but dexamethasone is predominantly metabolized and metabolites are excreted renally (~80% of dose) and fecally (~20%). |
| Half-life | Terminal elimination half-life is approximately 3-4 hours for dexamethasone, but due to the acetate ester in Decadron-LA, absorption is prolonged, leading to an extended duration of action. The apparent half-life after intramuscular administration is about 3-4 days (72-96 hours) due to slow release from the injection site. |
| Protein binding | Dexamethasone is approximately 77% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Vd for dexamethasone is approximately 0.8-1.0 L/kg (mean ~0.9 L/kg), indicating distribution into total body water. |
| Bioavailability | Oral: 80-90% (dexamethasone base). Intramuscular: 100% (assuming absorption from depot). Intravenous: 100%. |
| Onset of Action | Intramuscular: 1-2 hours for systemic effects (anti-inflammatory). Intra-articular/intralesional: 24-72 hours for local effects. Intravenous: immediate. Oral: within 1-2 hours. |
| Duration of Action | Intramuscular: 1-3 weeks depending on dose, due to slow release from the acetate salt. Intra-articular: 3 days to 3 weeks. Intravenous/oral: duration of action 12-36 hours (anti-inflammatory). |
| Molecular Weight | 434.5 Da (as dexamethasone sodium phosphate; dexamethasone base: 392.46 Da) |
Dexamethasone acetate (DECADRON-LA) 8-16 mg intramuscularly every 1-3 weeks; adjust based on response and tolerance.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required for GFR >10 mL/min; for GFR <10 mL/min, consider reducing dose by 25-50% due to prolonged half-life. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Reduce dose by 75% or use alternative with shorter half-life. |
| Pediatric use | 0.02-0.3 mg/kg/dose intramuscularly every 1-3 weeks; not to exceed 8 mg as initial dose; titrate based on response. |
| Geriatric use | Initiate at lower end of dosing range (8 mg intramuscularly) and titrate slowly due to increased risk of osteoporosis, hyperglycemia, and immunosuppression; monitor bone density and blood glucose. |
| 1st trimester | Corticosteroids like dexamethasone are associated with increased risk of cleft palate and intrauterine growth restriction. Use only if clearly indicated and benefit outweighs risk. |
| 2nd trimester | May cause fetal adrenal suppression, but used therapeutically for fetal lung maturity. Monitor for maternal glucose intolerance. |
| 3rd trimester | Prolonged use may lead to neonatal adrenal insufficiency. Use with caution; lowest effective dose for shortest duration. |
Clinical note
Comprehensive clinical and safety monograph for DECADRON-LA (DECADRON-LA).
| Placental transfer | Dexamethasone crosses the placenta; metabolized by placental 11β-HSD2 to a lesser extent than prednisolone, resulting in higher fetal exposure. Fetal levels are approximately 30-50% of maternal levels. |
| Breastfeeding | Dexamethasone is excreted into breast milk in low amounts. With high maternal doses, monitor infant for adrenal suppression. Short-term use is likely compatible; avoid prolonged high-dose therapy. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
Systemic fungal infectionsHypersensitivity to dexamethasone or any component
| Precautions | May cause immunosuppression and increase susceptibility to infections., Adrenal suppression with prolonged therapy; taper gradually., Exacerbation of systemic fungal infections; do not use in active fungal infections unless specific antifungal therapy is administered., Withdrawal symptoms including adrenal insufficiency, fever, myalgia, arthralgia, and malaise., Kaposi sarcoma has been reported; discontinuation may result in clinical remission., Avoid live vaccines in patients receiving immunosuppressive doses., Monitor blood pressure, blood glucose, and electrolytes during prolonged therapy. |
| Food/Dietary | Avoid excessive consumption of salt and potassium-rich foods if on high-dose or long-term therapy. Grapefruit juice may increase systemic exposure to dexamethasone; monitor for increased adverse effects. |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | First trimester: Increased risk of cleft palate (odds ratio 3.35) and cardiovascular defects. Second/third trimester: Fetal adrenal suppression, IUGR, oligohydramnios. Chronic use increases risk of preterm birth. |
| Fetal Monitoring | Blood pressure, blood glucose (maternal). Fetal ultrasound for growth and amniotic fluid index (every 4 weeks if chronic therapy). Fetal heart rate monitoring if preterm labor risk. |
| Fertility Effects | May inhibit ovulation (dose-dependent) via suppression of LH/FSH. Reversible upon discontinuation. No evidence of permanent infertility. |
| Clinical Pearls | Decadron-LA (dexamethasone acetate) is a long-acting injectable corticosteroid. It should be administered deep IM or intra-articularly; not for IV use. Onset is 24-48 hours with duration up to 2-3 weeks. Use caution in patients with diabetes as it can cause hyperglycemia. Avoid use in systemic fungal infections or during an active infection without concurrent antimicrobials. |
| Patient Advice | This medication is a long-acting steroid injection; full effects may take a few days to appear. · Report any signs of infection (fever, redness, swelling) or sudden mood changes to your healthcare provider. · Do not receive live vaccines while on this medication. · If you have diabetes, monitor your blood glucose more closely as this drug can raise blood sugar. · Inform all healthcare providers that you have received this injection, especially before any surgery. |